NeOnc Technologies Holdings, Inc. Common Stock (NTHI)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.75

+0.09 (+3.38%)

Market Cap: $76.62M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

0%(0/3)

Avg Surprise

-175.80%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.27

Range$-0.47 - $-0.08

4 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.21-29.8%

60d ago$-0.17-63.5%

30d ago$-0.34+18.7%

7d ago$-0.34+18.7%

Current$-0.27

Revenue Consensus

Range$0 - $0

5 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.72

Range$-1.32 - $-0.16

4 analysts

Revenue Consensus

Range$0 - $0

5 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.72	$-1.32 - $-0.16	-	-	4	-	-
Sep 30, 2026Sep 26EST	-	$-0.27	$-0.47 - $-0.08	-	-	4	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-0.58	$-0.16	$-0.26 - $-0.10	-262.50%	Miss	3	1 0 30d	-93.3%
Mar 31, 2026Mar 26 Reported May 18, 2026Reported May 18	$-0.38	$-0.14	$-0.14 - $-0.14	-171.43%	Miss	1	No revisions (30d)	+81.9%
Dec 31, 2025Dec 25 Reported Mar 31, 2026Reported Mar 31	$-0.72	$-0.37	$-0.37 - $-0.37	-93.46%	Miss	1	No revisions (30d)	-450.6%
Sep 30, 2025Sep 25 Reported Nov 14, 2025Reported Nov 14	$-0.45	N/A	-	N/A	Beat	-	-	-
Jun 30, 2025Jun 25 Reported Aug 18, 2025Reported Aug 18	$-0.30	N/A	-	N/A	Beat	-	-	-
Mar 31, 2025Mar 25 Reported Jun 6, 2025Reported Jun 6	$-2.10	N/A	-	N/A	Beat	-	-	-
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$-0.13	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.29	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-104419.00%
ROE	0.00%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	-9.93x
Current Ratio	0.18x	Quick Ratio	0.18x
Trading Statistics
Beta	N/A	Avg Volume	180.59K
52-Week High	$12.00	52-Week Low	$2.50

Technical Indicators Dashboard

Moving Averages

SMA 10$2.77

SMA 20$3.02

SMA 50$3.73

SMA 200$5.81

EMA 10$2.80

EMA 20$3.03

EMA 50$3.51

EMA 200$5.19

MACD

Line: -0.31Signal: -0.31Hist: -0.00

ADX

ADX: 24.8+DI: 11.8-DI: 20.5

Aroon & PSAR

Aroon Up8.0

Aroon Down84.0

PSAR$2.50

Bollinger Bands

Upper Band$3.61

Lower Band$2.43

%B Position3914%(Upper)

Band Width0.27

RSI (14-Day)

Neutral

40.2

Momentum Oscillators

Stoch %K16.4

Stoch %D16.5

Williams %R-75.1

ROC (10d)-10.1%

Momentum-0.31

CCI (20d)-78.9

MFI (14d)40.4

Volatility Measures

ATR (14d)$0.32(11.7%)

StdDev (20d)0.30

Hist Vol82.6%(High)

Volume Flow

VWAP$2.74

OBV-7.8M

AD Line-8.2M

CMF (20d)-0.381

Volume Metrics

Avg Vol (20d)169.4K

Vol Ratio0.6x

VWMA (20d)$3.03

Pivot Points

R3$3.02

R2$2.91

R1$2.78

Pivot Point$2.67

S1$2.54

S2$2.43

S3$2.30

Advanced Oscillators

TSI-23.34

Ultimate Osc38.6

KST-274.96

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$39,990	$20,000	$0	$20,000	$43,000	$0	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$230,000
Gross Profit	$0	$0	N/A	$0	$0	$39,990	$20,000	$0	$20,000	$43,000	N/A	$-230,000

Operating Expenses	$14.07M	$7.70M	$8.02M	$6.93M	$5.71M	$31.94M	$2.13M	$2.20M	$1.30M	$1.59M	$4.81M	$2.62M
R&D	$2.65M	$1.29M	$1.25M	$715,038	$677,332	$998,222	$1.08M	$956,725	$394,484	$614,517	$544,875	$402,831
SG&A	$895,559	$1.13M	$2.08M	$902,985	$984,262	$849,485	$730,737	$243,659	$289,652	$415,612	$761,812	$1.38M
Operating Income	$-14,069,887	$-7,055,662	$-8,020,951	$-6,934,647	$-5,708,034	$-31,900,842	$-2,113,732	$-2,197,187	$-1,280,120	$-1,551,483	$-4,806,687	$-2,617,607

Interest Income	$334	$5,196	$240,343	$6,815	$28,725	$51,699	$3,446	$12,687	$0	$0	$0	$0
Interest Expense	$402,321	$1.17M	$1.28M	$869,815	$48,750	$476,873	$-2,401	$0	$3.24M	$1.39M	$1.35M	$976,703
Income Before Tax	$-14,050,417	$-8,819,932	$-9,607,995	$-8,615,920	$-5,680,170	$-32,326,016	$-2,252,982	$-2,184,500	$-4,522,006	$-2,938,976	$-6,155,249	$-3,594,310
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-14,240,044	$-8,819,932	$-9,848,133	$-8,615,920	$-5,680,170	$-32,326,016	$-2,252,982	$-2,184,500	$-4,522,006	$-2,938,976	$-6,155,249	$-3,594,310

EBITDA	$-13,454,944	$-6,781,593	$-8,622,085	$-7,342,742	$-5,449,743	$-31,323,650	$-2,046,656	$-2,130,111	$-1,168,327	$-1,551,483	$-4,806,687	$-2,617,607
EBIT	$-13,648,430	$-7,005,738	$-8,571,258	$-7,752,920	$-5,660,145	$-31,900,842	$-2,258,829	$-2,197,187	$-1,280,120	$-1,551,483	$-4,806,687	$-2,617,607

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NTHI

News

A 3-year-old with a brain tumor is beginning to move his legs after an experimental nasal treatment.

NeOnc Technologies Holdings (NTHI) reported early improvement in a three-year-old critically ill child with a brain tumor receiving investigational NEO100 through a Compassionate Care program. The child is now breathing...

Stock Titan•Oct 16, 2026 9:09 AM ET10/16/26•Bullish

NeOnc Technologies Reports Early Clinical Improvement in Compassionate-Use NEO100 Patient in Abu Dhabi

NeOnc Technologies Holdings, Inc. announced early clinical improvement in a three-year-old boy with an aggressive brain tumor receiving investigational intranasal NEO100 through a Compassionate Care program in Abu Dhabi....

Quiver Quantitative•Oct 16, 2026 8:09 AM ET10/16/26•Somewhat-Bullish

Three-year-old boy shows early improvement after receiving investigational brain tumor treatment NEO100 in Abu Dhabi

NeOnc Technologies reported early clinical improvement in a three-year-old boy with an aggressive brain tumor, who received the investigational intranasal treatment NEO100 under compassionate use in Abu Dhabi. While...

Pluang•Oct 16, 2026 8:09 AM ET10/16/26•Bullish

NeOnc reports clinical improvement in compassionate use patient By Investing.com

NeOnc Technologies Holdings Inc. (NASDAQ:NTHI) reported clinical improvement in a three-year-old patient with an aggressive brain tumor through its Compassionate Care program. The patient...

Investing.com Canada•Oct 16, 2026 8:09 AM ET10/16/26•Somewhat-Bullish

NeOnc Technologies (NTHI) lists Ali Mohammad Ahmad Mohammad Alabedin as a director.

NeOnc Technologies Holdings, Inc. (NTHI) has identified Ali Mohammad Ahmad Mohammad Alabedin as a director through a Form 3 ownership filing. The filing indicates that Alabedin's event date requiring the statement was...

Stock Titan•Oct 15, 2026 9:09 PM ET10/15/26•Somewhat-Bullish

NTHI Valuation and Fair Value

P/E: -1.3x
P/B: -3.7x

See GNG's fair value

NTHI Profitability: Margins, ROIC and FCF

Operating margin: -104419.0%
Net margin: 0.0%
ROE: 0.0%

NTHI Competitors

Company	Ticker
Nutriband Inc	NTRB
Cognition Therapeutics Inc	CGTX
Telomir Pharmaceuticals, Inc. Common Stock	TELO
Electrocore LLC	ECOR
Pelthos Therapeutics Inc.	PTHS
InterCure Ltd.	INCR
Kazia Therapeutics Ltd ADR	KZIA
CareCloud, Inc.	CCLD

Sector: Healthcare

NTHI Analyst Ratings

Consensus: Buy
Analysts: 3
Strong Buy: 1
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

NTHI Bull Case vs Bear Case

Bear case

NTHI's quarterly revenue changed -100.0% year over year.

NTHI Earnings: Beat Rate and Next Report

Beat rate: 0 of 4 quarters (0.0%)
Average surprise: -175.8%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.27
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

Frequently Asked Questions About NTHI

Does NTHI pay dividends?

NeOnc Technologies Holdings, Inc. Common Stock (NTHI) does not currently pay a regular dividend.

What is NTHI's market cap?

NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has a market capitalization of $76.62M with a current stock price of $2.75.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In